Evidence highlighted in an article published in Clinical Pharmacology and Therapeutics further supports the urgent need for a full clinical trial of a candidate already selected by CPT’s International Linked Clinical Trial experts and for which CPT continues to seek funding: N- acetyl cysteine.

CPT’s research team comment that  

“Again evidence accumulates to support the trial of candidates selected by its LCT committee but struggling to find funding because of their limited or absent commercial potential; this time N-acetyl cysteine (NAC). Although this is a small study with only short term outcomes it further corroborates evidence accumulated by CPT to date of its potential utility in PD. NAC is currently approved for the treatment of mucus secretions in pulmonary disease and the treatment of acetaminophen (Paracetamol) overdose. NAC is also available universally as a non-regulated nutritional supplement.” 

You can read more about NAC here